Unlock instant, AI-driven research and patent intelligence for your innovation.

Intermediate compound of antitumor drug neratinib and its preparation method and use

The technology of a compound and a compound of general formula is applied in the application field of preparing neratinib, which can solve problems such as low yield, adverse effects on health, and environmental pollution

Active Publication Date: 2015-02-04
SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI +2
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] The disadvantage of this process is that the reaction conditions are relatively harsh and the yield is low, the formation of the quinoline ring needs to be carried out at high temperature, the volatilization of the solvent will have an adverse effect on the health of the operator, and it will easily pollute the environment; the route It is only suitable for laboratory-scale production. In commercial-scale production (kg level), the purity and yield cannot meet the requirements, so people are still constantly exploring new synthetic routes

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Intermediate compound of antitumor drug neratinib and its preparation method and use
  • Intermediate compound of antitumor drug neratinib and its preparation method and use
  • Intermediate compound of antitumor drug neratinib and its preparation method and use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0116] Example 1 Preparation of 3-crotonamido-4-ethoxybenzoic acid methyl ester

[0117]

[0118] Add methyl 3-amino-4-ethoxybenzoate (1.6g, 8mmol) (commercially purchased), THF (5mL), water (0.1mL), potassium carbonate (3.1g, 22mmol), ice Add crotonyl chloride (0.86g, 8mmol) under stirring in the bath, and after stirring for half an hour, the reaction solution is concentrated to dryness. After cooling in an ice-water bath, adjust the pH to 4-5 with dilute hydrochloric acid, and a white solid product precipitates out. Half an hour later, it was filtered and slurried with ethyl acetate to obtain 1.85 g of the title compound as a white powder, with a yield of 86%. 1 HNMR (400MHz, CDCl 3 ): δ1.52(t, 3H), 1.96(d, 3H), 3.90(s, 3H), 4.20(q, 2H), 6.02(d, 1H), 6.91(d, 1H), 7.03(m, 1H), 7.74(s, 1H), 7.80(dd, 1H), 9.12(s, 1H).

Embodiment 2

[0119] Example 2 Preparation of 2-nitro-5-crotonamido-4-ethoxybenzoic acid methyl ester

[0120]

[0121] The compound of Example 1 (1.8g, 7mmol) and dichloromethane (15mL) were sequentially added into the one-necked flask, and fuming nitric acid (1.2g, 20mmol) was added with stirring in an ice bath. After the addition was complete, the reaction was continued for 5 hours. The reaction solution was poured into ice water, extracted with dichloromethane, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated to dryness, and beaten with ethyl acetate to obtain 1.32 g of the light yellow title compound with a yield of 65%. 1 HNMR (300MHz, CDCl 3 ): δ1.54(t, 3H), 1.96(d, 3H), 3.90(s, 3H), 4.24(q, 2H), 6.02(d, 1H), 7.04(m, 1H), 7.46(s, 1H), 7.87(s, 1H), 8.84(s, 1H).

Embodiment 3

[0122] Example 3 Preparation of 2-amino-5-crotonamido-4-ethoxybenzoic acid methyl ester

[0123]

[0124] Add embodiment 2 compound (1.28g, 4mmol) successively in one-necked bottle, CH 3 COOH (10 mL), zinc powder (0.81 g, 12 mmol) was added in batches under stirring in an ice bath, and after the addition was complete, the reaction was continued for another 2 hours. The reaction solution was filtered, concentrated to remove most of the acetic acid, and saturated aqueous sodium bicarbonate (10 mL) was added. Each was extracted three times with dichloromethane (10 mL), dried, concentrated, and the solid was slurried with ethyl acetate to obtain 0.9 g of the off-white title compound with a yield of 78%. 1 HNMR (300MHz, CDCl 3 ): δ1.46(t, 3H), 1.91(d, 3H), 3.83(s, 3H), 4.08(q, 2H), 5.94(dd, 1H), 6.10(s, 1H), 6.95(m, 1H), 7.40(s, 1H), 8.87(s, 1H).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an intermediate compound of an antitumor drug neratinib, or its acid addition salt, and its preparation method and use in preparation of neratinib. The intermediate compound is shown in the formula I. In the formula I, A represents hydrogen, a leaving group or dimethylamino; the leaving group is halogen, mesyloxy, trifluorinated mesyloxy or methylphenylsulfonyloxy; and the acid addition salt of the intermediate compound is an inorganic acid salt or an organic acid salt of the intermediate compound shown in the formula I when A represents dimethylamino.

Description

technical field [0001] The present invention relates to a new intermediate for preparing neratinib (neratinib, HKI-272) and its preparation method and its application in the preparation of neratinib. More specifically, it relates to a compound whose structural formula is shown in the following formula I, a preparation method thereof and its application in the preparation of Neratinib. Background technique [0002] Neratinib (neratinib, HKI-272) is an oral irreversible pan-ErbB receptor tyrosine kinase inhibitor that is currently undergoing phase III clinical trials worldwide by Pfizer, which can effectively inhibit ErbB1 and ErbB2 tyrosine Kinase activity, the mechanism of its action is to inhibit the ATP sites of EGFR (ErbB-1) and HER2 (ErbB-2) in cells to prevent phosphorylation and activation of tumor cells, through EGFR (ErbB-1) and HER2 (ErbB-2) ) homogeneous and heterogeneous dimers block the down-regulation signal, so as to achieve the purpose of tumor control. For ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D215/56C07D401/12C07C255/24C07C233/55C07C237/16C07D215/54
Inventor 张容霞刘正张强夏祥飞吴明军陈基陈伟铭李剑峰沈敬山
Owner SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI